血清PDCD5、PCNA表达与非小细胞肺癌患者临床病理特征及近期预后的关系

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (676 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expressions of programmed cell death 5 (PDCD5) and proliferating cell nuclear antigen (PCNA) in serum of patients with non-small cell lung cancer (NSCLC) and their relationship with the short-term prognosis. Methods From February 2017 to February 2018, 79 cases with NSCLC patients who diagnosed and treated in Suzhou Municipal Hospital of Anhui Province were selected as cancer group, and 40 healthy medical examinees in the same period were used as control group. Enzyme-linked immunosorbent assay was used to detect the expression of PDCD5 and PCNA in the serum of two groups. The relationship between PDCD5, PCNA expression and clinicopathological characteristics of NSCLC patients were analyzed. The relationship between different levels of PDCD5 and PCNA expressions and the 1-year overall survival (OS) rate in NSCLC patients were analyzed. Results The expression levels of PDCD5 in cancer group were lower than those in control group, while the expression levels of PCNA in cancer group were higher than those in control group, and the difference was statistically significant(P < 0.05). The expressions of PDCD5 and PCNA in serum of the cancer group were related to TNM stage and lymph node metastasis (P < 0.05). Serum PDCD5 was significantly negatively correlated with PCNA expression (r = -0.621, P = 0.000). Patients with low PDCD5 expression had lower OS than patients with high PDCD5 expression for 1-year (P < 0.05). The 1-year OS of patients with high PCNA expression was lower than that of patients with low PCNA expression (P < 0.05). Conclusion The expression of serum PDCD5 of NSCLC patients is decreased, while the expression of PCNA is increased, which are related to the staging of TNM and lymph node metastasis, and are expected to become a new tumor marker in NSCLC serum.

Key words： Non-small cell lung cancer Programmed cell death 5 Proliferating cell nuclear antigen Short-term prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Duan WANG Anhui FU Wensheng

Cite this article:

WANG Duan WANG Anhui FU Wensheng. Relationship between serum PDCD5 and PCNA expression with clinicopathological characteristics and short-term prognosis in patients with non-small cell lung cancer[J]. 中国医药导报, 2020, 17(14): 98-101.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I14/98

[1] Mao Y，Yang D，He J，et al. Epidemiology of Lung Cancer [J]. Surg Oncol Clin N Am，2016，25（3）：439-445.
[2] 黄亚，张西志.非小细胞肺癌综合治疗中的放疗联合免疫治疗[J].实用临床医药杂志，2019，23（14）：7-11.
[3] 孔德琦，刘苓霜，姜怡，等.中医药干预Ⅲa期非小细胞肺癌根治术后无病生存期及预后相关因素分析[J].国际中医中药杂志，2019，41（1）：8-13.
[4] Li G，Ma D，Chen Y. Cellular functions of programmed cell death 5 [J]. Biochim Biophys Acta，2016，1863（4）：572-580.
[5] Gao L，Ye X，Ma RQ，et al. Low programmed cell death 5 expression is a prognostic factor in ovarian cancer [J]. Chin Med J（Engl），2015，128（8）：1084-1090.
[6] Prestel A，Wichmann N，Martins JM，et al. The PCNA interaction motifs revisited：thinking outside the PIP-box [J]. Cell Mol Life Sci，2019，76（24）：4923-4943.
[7] Cai F，Li J，Pan X，et al. Increased Expression of PCNA-AS1 in Colorectal Cancer and its Clinical Association [J]. Clin Lab，2017，63（11）：1809-1814.
[8] 王飞.PDCD5和PCNA在肺癌患者血清中的表达[J].浙江实用医学，2018，23（1）：8-9，18.
[9] Jang N，Choi JE，Kang SH，et al. Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer [J]. Virchows Arch，2019，474（2）：193-200.
[10] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[11] 方平，王沣，江富来，等.非小细胞肺癌表皮生长因子受体突变的检测与分子靶向治疗[J].中华肺部疾病杂志：电子版，2017，10（5）：543-548.
[12] 徐燕，田春香，刘武，等.化疗序贯靶向药物治疗表皮生长因子受体-酪氨酸激酶抑制剂获得性耐药老年晚期非小细胞肺癌患者临床研究[J].肿瘤研究与临床，2018， 30（9）：617-620.
[13] Singh R，Letai A，Sarosiek K. Regulation of apoptosis in health and disease：the balancing act of BCL-2 family proteins [J]. Nat Rev Mol Cell Biol，2019，20（3）：175-193.
[14] Kwak S，Lee SH，Han EJ，et al. Serine/threonine kinase 31 promotes PDCD5-mediated apoptosis in p53-dependent human colon cancer cells [J]. J Cell Physiol，2019，234（3）：2649-2658.
[15] Qiao F，Gong P，Song Y，et al. Downregulated PITX1 Modulated by MiR-19a-3p Promotes Cell Malignancy and Predicts a Poor Prognosis of Gastric Cancer by Affecting Transcriptionally Activated PDCD5 [J]. Cell Physiol Biochem，2018，46（6）：2215-2231.
[16] Li P，Fei H，Wang L，et al. PDCD5 regulates cell proliferation，cell cycle progression and apoptosis [J]. Oncol Lett，2018，15（1）：1177-1183.
[17] De March M，De Biasio A. The dark side of the ring：role of the DNA sliding surface of PCNA [J]. Crit Rev Biochem Mol Biol，2017，52（6）：663-673.
[18] Mestrinho LA，Faísca P，Peleteiro MC，et al. PCNA and grade in 13 canine oral squamous cell carcinomas association with prognosis [J]. Vet Comp Oncol，2017，15（1）：18-24.
[19] Wang Y，Chen T，Huang H，et al. miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma [J]. Oncotarget，2017，8（12）：20133-20144.
[20] Gary R，Ludwig DL，Cornelius HL，et al. The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen （PCNA） and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21 [J]. J Biol Chem，1997，272（39）：24522-24529.
[21] Li X，Xie W，Xie C，et al. Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation [J]. Phytother Res，2014，28（10）：1553-1560.